[go: up one dir, main page]

MX2017012834A - Anticuerpos anti-c1s humanizados y metodos para usarlos. - Google Patents

Anticuerpos anti-c1s humanizados y metodos para usarlos.

Info

Publication number
MX2017012834A
MX2017012834A MX2017012834A MX2017012834A MX2017012834A MX 2017012834 A MX2017012834 A MX 2017012834A MX 2017012834 A MX2017012834 A MX 2017012834A MX 2017012834 A MX2017012834 A MX 2017012834A MX 2017012834 A MX2017012834 A MX 2017012834A
Authority
MX
Mexico
Prior art keywords
humanized anti
antibodies
present description
description provides
methods
Prior art date
Application number
MX2017012834A
Other languages
English (en)
Other versions
MX389703B (es
Inventor
Panicker Sandip
Parry Graham
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of MX2017012834A publication Critical patent/MX2017012834A/es
Publication of MX389703B publication Critical patent/MX389703B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21106—Hepsin (3.4.21.106)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21042—Complement subcomponent C1s (3.4.21.42)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción proporciona anticuerpos anti-C1s humanizados. La presente descripción proporciona ácidos nucleicos que comprenden secuencias de nucleátidos que codifican los anticuerpos anti-C1s humanizados; y las células hospedadoras que comprenden los ácidos nucleicos. La presente descripción proporciona composiciones que comprenden los anticuerpos anti-C1s humanizados. La presente descripción proporciona métodos de uso de los anticuerpos anti-C1s humanizados.
MX2017012834A 2015-04-06 2016-04-05 Anticuerpos anti-c1s humanizados y metodos para usarlos. MX389703B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562143636P 2015-04-06 2015-04-06
US201562200997P 2015-08-04 2015-08-04
PCT/US2016/026038 WO2016164358A1 (en) 2015-04-06 2016-04-05 Humanized anti-c1s antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2017012834A true MX2017012834A (es) 2018-05-28
MX389703B MX389703B (es) 2025-03-20

Family

ID=57073330

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012834A MX389703B (es) 2015-04-06 2016-04-05 Anticuerpos anti-c1s humanizados y metodos para usarlos.
MX2022001085A MX2022001085A (es) 2015-04-06 2017-10-05 Anticuerpos anti-c1s humanizados y metodos para usarlos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022001085A MX2022001085A (es) 2015-04-06 2017-10-05 Anticuerpos anti-c1s humanizados y metodos para usarlos.

Country Status (26)

Country Link
US (3) US10729767B2 (es)
EP (2) EP4212175A1 (es)
JP (4) JP7005483B2 (es)
KR (2) KR20250011240A (es)
CN (2) CN108348598B (es)
AU (3) AU2016246452B2 (es)
CA (1) CA2981321A1 (es)
CL (1) CL2017002514A1 (es)
CO (1) CO2017011238A2 (es)
DK (1) DK3280440T5 (es)
EA (1) EA201792080A1 (es)
ES (1) ES2938359T3 (es)
FI (1) FI3280440T3 (es)
HK (1) HK1259251A1 (es)
HR (1) HRP20230093T1 (es)
HU (1) HUE061076T2 (es)
IL (3) IL318523A (es)
LT (1) LT3280440T (es)
MX (2) MX389703B (es)
PH (2) PH12017501815B1 (es)
PL (1) PL3280440T3 (es)
PT (1) PT3280440T (es)
RS (1) RS63956B1 (es)
SG (2) SG11201707886WA (es)
SI (1) SI3280440T1 (es)
WO (1) WO2016164358A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd MOUSE FC RII SPECIFIC FC ANTIBODY
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
PT2914291T (pt) 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
ES2938359T3 (es) 2015-04-06 2023-04-10 Bioverativ Usa Inc Anticuerpos humanizados anti-C1s y métodos de uso de los mismos
FI3525583T3 (fi) * 2016-10-12 2025-10-31 Bioverativ Usa Inc Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
WO2019098212A1 (en) 2017-11-14 2019-05-23 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
AU2019250403A1 (en) * 2018-04-13 2020-11-19 Chugai Seiyaku Kabushiki Kaisha Anti-complement component antibodies and methods of use
BR112021021689A2 (pt) 2019-05-15 2022-03-22 Chugai Pharmaceutical Co Ltd Molécula de ligação a antígeno, composição farmacêutica, e método
CA3187866A1 (en) 2020-08-06 2022-02-10 Jaime Morales ARIAS Inflammatory cytokines and fatigue in subject with a complement mediated disease
CN117241828A (zh) 2021-03-31 2023-12-15 美国比奥维拉迪维股份有限公司 减少冷凝集素病患者的手术相关溶血
CN117769434A (zh) * 2021-05-20 2024-03-26 黛安瑟斯医疗运营公司 与C1s结合的抗体和其用途
WO2023287573A2 (en) 2021-07-13 2023-01-19 Mabwell Therapeutics Inc. Anti-c1s antibodies and uses thereof
EP4539881A1 (en) 2022-06-15 2025-04-23 Bioverativ USA Inc. Anti-complement c1s antibody formulation
AU2023286689A1 (en) 2022-06-24 2025-02-06 Bioverativ Usa Inc. Methods for treating complement-mediated diseases
AU2024237478A1 (en) 2023-03-16 2025-10-30 Genzyme Corporation Treatment of dry age-related macular degeneration

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60192263A (ja) 1984-03-13 1985-09-30 Teijin Ltd 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
ES2171465T3 (es) 1993-09-01 2002-09-16 Sanquin Bloedvoorziening Inhibidor de la esterasa de c1 para reducir lesiones de miocardio durante un infarto de miocardio agudo.
PL186073B1 (pl) 1993-10-25 2003-10-31 Canji Preparat farmaceutyczny, zwłaszcza do terapii genowej
CN1160469C (zh) 1994-12-09 2004-08-04 帝国大学改革有限公司 基因的鉴定
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
EP1152759A2 (en) 1999-02-09 2001-11-14 3-Dimensional Pharmaceuticals, Inc. METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
WO2000064327A2 (en) 1999-04-26 2000-11-02 Duke University Inhibition of complement action
WO2001013945A1 (en) 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
ES2299473T3 (es) 2000-01-31 2008-06-01 Pharming Intellectual Property B.V. Inhibidor de c1 humano producido en la leche de mamiferos transgenicos.
ES2329010T3 (es) 2000-03-23 2009-11-20 Genentech, Inc. Inhibidores anti-c2/c2a de la activacion del complemento.
US7071299B2 (en) 2000-06-21 2006-07-04 Zymogenetics, Inc. Peptide and polypeptide inhibitors of complement C1s
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
EP1416962A4 (en) 2001-07-26 2006-05-24 Alexion Pharma Inc METHOD FOR IMPROVING THE COGNITIVE FUNCTION
US20080206242A1 (en) * 2002-03-01 2008-08-28 Xencor, Inc. Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
SE0202880D0 (sv) 2002-07-26 2002-09-30 Wieslab Ab Complement system deficiency assay
US7666627B2 (en) 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
AU2003270330B2 (en) 2002-09-06 2009-07-30 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component C5
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
AU2004241069B2 (en) 2003-05-15 2010-09-09 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005025509A2 (en) 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US20080075712A1 (en) 2003-10-14 2008-03-27 Kunihiro Hattori Double Specific Antibodies Substituting For Functional Proteins
WO2005056759A2 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
HRP20130440T1 (en) 2004-04-13 2013-06-30 F. Hoffmann - La Roche Ag Anti-p-selectin antibodies
CA2847677C (en) 2004-06-10 2018-05-01 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US20060018896A1 (en) 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1819731A4 (en) 2004-12-08 2013-02-13 Immunomedics Inc METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER
ATE450522T1 (de) 2005-03-16 2009-12-15 Janssen Pharmaceutica Nv Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
WO2006131874A2 (en) 2005-06-06 2006-12-14 Univ Cape Town Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
AU2006304804B2 (en) 2005-10-21 2011-06-02 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
WO2007070375A2 (en) 2005-12-09 2007-06-21 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US9480658B2 (en) 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
AU2006327989B2 (en) 2005-12-21 2012-06-07 Pharming Intellectual Property Bv Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
FR2897868B1 (fr) 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
KR101513308B1 (ko) 2006-03-08 2015-04-28 아케믹스 엘엘씨 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제
BRPI0715869A2 (pt) 2006-09-05 2013-07-30 Alexion Pharma Inc mÉtodos e composiÇÕes para o tratamento de neuropatias mediadas por anticorpos
SI3028716T1 (sl) 2006-10-10 2021-01-29 Regenesance B.V. Komplementarna inhibicija za izboljšano regeneracijo živcev
JP5586961B2 (ja) 2006-12-19 2014-09-10 バーシテック、リミテッド 合成イオンチャネル
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
SI2176296T1 (sl) 2007-07-16 2012-05-31 Genentech Inc Protitelesa proti CD b in imunokonjugati in postopki za uporabo
US8236307B2 (en) 2007-08-03 2012-08-07 Genentech, Inc. Humanized anti-FGF19 antagonists and methods using same
WO2009121065A2 (en) 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
AU2009239437B2 (en) 2008-04-25 2014-11-13 University Of Washington Levels of BCMA protein expression on B cells and use in diagnostic methods
WO2009151634A1 (en) 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
EP2894166A1 (en) 2008-11-10 2015-07-15 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP3460480B1 (en) 2008-12-01 2022-11-02 The Board of Trustees of the Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
US8401799B2 (en) 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
NZ597259A (en) 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
KR101759895B1 (ko) 2009-10-16 2017-07-20 오메로스 코포레이션 Ｍａｓｐ－2 의존성 보체 활성화의 억제에 의한 파종성 혈관내 응고의 치료 방법
WO2011102342A1 (ja) * 2010-02-16 2011-08-25 国立大学法人京都工芸繊維大学 抗体固定化担体、抗体固定化担体の製造方法および当該抗体固定化担体の利用
SG183541A1 (en) 2010-03-01 2012-10-30 Alexion Pharma Inc Methods and compositions for treating degos' disease
PT2563813E (pt) 2010-04-30 2015-11-26 Alexion Pharma Inc Anticorpos anti-c5a e métodos para utilização dos anticorpos
US9090674B2 (en) 2010-05-17 2015-07-28 The Board Of Regents Of The University Of Texas System Rapid isolation of monoclonal antibodies from animals
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
AU2011270959A1 (en) 2010-06-22 2013-01-10 Musc Foundation For Research Development Antibodies to the C3d fragment of complement component 3
UY33578A (es) 2010-08-31 2012-03-30 Sanofi Sa PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US8865164B2 (en) 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
SI2648752T1 (sl) 2010-12-06 2017-06-30 Seattle Genetics, Inc. Humanizirana protitelesa proti Liv-1 in njihova uporaba za zdravljenje raka
EP3287142B1 (en) 2011-04-08 2021-08-04 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
RS60541B1 (sr) 2011-05-04 2020-08-31 Omeros Corp Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
DK2793935T3 (en) 2011-12-22 2016-09-05 Csl Behring Gmbh Use of C1 inhibitor in the treatment of secondary edema in the central nervous system.
JP6081699B2 (ja) * 2011-12-28 2017-02-15 雅史 溝上 Ｉｌ−２８ｂの分析方法
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
PT2914291T (pt) 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
KR101638931B1 (ko) 2013-01-31 2016-07-12 서울대학교산학협력단 보체 관련 질환의 예방 및 치료를 위한 ｃ5 항체 및 방법
EA037325B1 (ru) 2013-07-09 2021-03-12 Аннексон, Инк. Антитела против фактора комплемента c1q и их применения
WO2015084999A1 (en) 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays
ES2938359T3 (es) 2015-04-06 2023-04-10 Bioverativ Usa Inc Anticuerpos humanizados anti-C1s y métodos de uso de los mismos
US20180169240A1 (en) 2015-06-26 2018-06-21 Bioverativ Usa Inc. Methods of treating autoimmune and alloimmune disorders
FI3525583T3 (fi) 2016-10-12 2025-10-31 Bioverativ Usa Inc Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
JP7293122B2 (ja) 2017-03-14 2023-06-19 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体が媒介する疾患および障害を処置するための方法

Also Published As

Publication number Publication date
PH12022551095A1 (en) 2023-02-27
CO2017011238A2 (es) 2018-01-16
KR20180006379A (ko) 2018-01-17
CL2017002514A1 (es) 2018-04-20
US20200405852A1 (en) 2020-12-31
WO2016164358A1 (en) 2016-10-13
KR102754975B1 (ko) 2025-01-14
IL318523A (en) 2025-03-01
KR20250011240A (ko) 2025-01-21
PH12017501815B1 (en) 2023-09-20
CN117285634A (zh) 2023-12-26
US10729767B2 (en) 2020-08-04
IL254670B (en) 2022-12-01
PL3280440T3 (pl) 2023-06-19
IL298180A (en) 2023-01-01
AU2016246452B2 (en) 2022-03-10
EP3280440A1 (en) 2018-02-14
SG11201707886WA (en) 2017-10-30
AU2022203679A1 (en) 2022-06-16
AU2025252590A1 (en) 2026-01-22
FI3280440T3 (fi) 2023-03-09
HK1250930A1 (en) 2019-01-18
JP2021006544A (ja) 2021-01-21
EP3280440B1 (en) 2022-11-16
PH12017501815A1 (en) 2018-04-23
CA2981321A1 (en) 2016-10-13
MX389703B (es) 2025-03-20
HK1259251A1 (zh) 2019-11-29
BR112017021289A2 (en) 2018-06-26
IL254670A0 (en) 2017-11-30
JP7005483B2 (ja) 2022-02-10
HRP20230093T1 (hr) 2023-03-31
RS63956B1 (sr) 2023-02-28
HUE061076T2 (hu) 2023-05-28
DK3280440T3 (da) 2023-02-20
SI3280440T1 (sl) 2023-03-31
MX2022001085A (es) 2022-02-14
EA201792080A1 (ru) 2018-03-30
SG10201909180SA (en) 2019-11-28
JP2024133591A (ja) 2024-10-02
PT3280440T (pt) 2023-02-14
IL298180B1 (en) 2025-02-01
EP3280440A4 (en) 2018-08-29
EP4212175A1 (en) 2023-07-19
DK3280440T5 (da) 2024-10-07
IL254670B2 (en) 2023-04-01
LT3280440T (lt) 2023-02-27
IL298180B2 (en) 2025-06-01
US20230218753A1 (en) 2023-07-13
CN108348598B (zh) 2023-09-01
ES2938359T3 (es) 2023-04-10
AU2022203679B2 (en) 2025-07-17
JP7153696B2 (ja) 2022-10-14
JP7518114B2 (ja) 2024-07-17
JP2022078221A (ja) 2022-05-24
CN108348598A (zh) 2018-07-31
US20180092974A1 (en) 2018-04-05
AU2016246452A1 (en) 2017-10-19
JP2018513213A (ja) 2018-05-24
US11246926B2 (en) 2022-02-15

Similar Documents

Publication Publication Date Title
MX2017012834A (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
AR132094A2 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
ECSP18094829A (es) Anticuerpos anti-cd40 y sus usos
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
CL2018000479A1 (es) Linfoopeitina strimal tomica (tslp) - anticuerpos de union y metodos de uso de los anticuerpos
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
AR110677A1 (es) Anticuerpos anti-c1s y métodos para usarlos
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
GT201700131A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
SV2018005624A (es) Anticuerpos anti-cd154 y metodos de uso de estos
CO2020005371A2 (es) Anticuerpos anti-apoc3 y métodos de uso de estos
AR103294A1 (es) Composiciones y procedimientos para la glicosilación de proteínas